EC approves Roche’s Hemlibra for hemophilia A

Roche (SIX:ROG; OTCQX:RHHBY) said the European Commission approved once-weekly subcutaneous Hemlibra emicizumab for routine prophylaxis of bleeding episodes in hemophilia A patients with Factor VIII inhibitors.

The pharma said it will work with EU member states to provide access to Hemlibra as quickly as possible. Roche also said it cannot comment on the price of the drug in specific countries at this time. In January, EMA's CHMP recommended approval of the bispecific mAb that binds Factor IXa and Factor X (see BioCentury, Feb.2)...